Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGarcía-Pérez, Javier
dc.contributor.authorGonzález Pérez, Maria
dc.contributor.authorCastillo de la Osa, María
dc.contributor.authorBorobia, Alberto M.
dc.contributor.authorCastaño, Luis
dc.contributor.authorBertrán, María Jesús
dc.contributor.authorCampins Martí, Magda
dc.contributor.authorFuentes Camps, Inmaculada
dc.contributor.authorAgustí Escasany, Maria Antònia
dc.date.accessioned2022-09-13T12:39:42Z
dc.date.available2022-09-13T12:39:42Z
dc.date.issued2022-08
dc.identifier.citationGarcía-Pérez J, González-Pérez M, Castillo de la Osa M, Borobia AM, Castaño L, Bertrán MJ, et al. Immunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study. eClinicalMedicine. 2022 Aug;50:101529.
dc.identifier.issn2589-5370
dc.identifier.urihttp://hdl.handle.net/11351/8185
dc.descriptionHeterologous vaccination; Neutralisation; SARS-CoV-2
dc.description.abstractBackground The CombiVacS study was designed to assess immunogenicity and reactogenicity of the heterologous ChAdOx1-S/BNT162b2 combination, and 14-day results showed a strong immune response. The present secondary analysis addresses the evolution of humoral and cellular response up to day 180. Methods Between April 24 and 30, 2021, 676 adults primed with ChAdOx1-S were enrolled in five hospitals in Spain, and randomised to receive BNT162b2 as second dose (interventional group [IG]) or no vaccine (control group [CG]). Individuals from CG received BNT162b2 as second dose and also on day 28, as planned based on favourable results on day 14. Humoral immunogenicity, measured by immunoassay for SARS-CoV-2 receptor binding domain (RBD), antibody functionality using pseudovirus neutralisation assays for the reference (G614), Alpha, Beta, Delta, and Omicron variants, as well as cellular immune response using interferon-γ and IL-2 immunoassays were assessed at day 28 after BNT162b2 in both groups, at day 90 (planned only in the interventional group) and at day 180 (laboratory data cut-off on Nov 19, 2021). This study was registered with EudraCT (2021-001978-37) and ClinicalTrials.gov (NCT04860739). Findings In this secondary analysis, 664 individuals (441 from IG and 223 from CG) were included. At day 28 post vaccine, geometric mean titres (GMT) of RBD antibodies were 5616·91 BAU/mL (95% CI 5296·49–5956·71) in the IG and 7298·22 BAU/mL (6739·41–7903·37) in the CG (p < 0·0001). RBD antibodies titres decreased at day 180 (1142·0 BAU/mL [1048·69–1243·62] and 1836·4 BAU/mL [1621·62–2079·62] in the IG and CG, respectively; p < 0·0001). Neutralising antibodies also waned from day 28 to day 180 in both the IG (1429·01 [1220·37–1673·33] and 198·72 [161·54–244·47], respectively) and the CG (1503·28 [1210·71–1866·54] and 295·57 [209·84–416·33], respectively). The lowest variant-specific response was observed against Omicron-and Beta variants, with low proportion of individuals exhibiting specific neutralising antibody titres (NT50) >1:100 at day 180 (19% and 22%, respectively). Interpretation Titres of RBD antibodies decay over time, similar to homologous regimes. Our findings suggested that delaying administration of the second dose did not have a detrimental effect after vaccination and may have improved the response obtained. Lower neutralisation was observed against Omicron and Beta variants at day 180.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofserieseClinicalMedicine;50
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia) - Vacunació
dc.subjectImmunoglobulines
dc.subjectCOVID-19 (Malaltia) - Prevenció
dc.subject.meshImmunogenicity, Vaccine
dc.subject.meshAntibodies, Neutralizing
dc.subject.meshCoronavirus Infections
dc.subject.mesh/prevention & control
dc.titleImmunogenic dynamics and SARS-CoV-2 variant neutralisation of the heterologous ChAdOx1-S/BNT162b2 vaccination: Secondary analysis of the randomised CombiVacS study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.eclinm.2022.101529
dc.subject.decsinmunogenicidad vacunal
dc.subject.decsanticuerpos neutralizantes
dc.subject.decsinfecciones por Coronavirus
dc.subject.decs/prevención & control
dc.relation.publishversionhttps://doi.org/10.1016/j.eclinm.2022.101529
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[García-Pérez J] Unidad de Inmunopatología del SIDA, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [González-Pérez M] Laboratorio de Referencia en Inmunología, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Castillo de la Osa M] Laboratorio de Serología, Centro Nacional de Microbiología, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. [Borobia AM] Servicio de Farmacología Clínica, Departamento de Farmacología y Terapéutica, Facultad de Medicina, Hospital Universitario La Paz, IdiPAZ, Universidad Autónoma de Madrid, Madrid, Spain. [Castaño L] Biocruces Bizkaia, Hospital Universitario Cruces, CIBERDEM, CIBERER, Endo-ERN, UPV-EHU, Barakaldo, Spain. [Bertrán MJ] Servicio de Medicina Preventiva y Epidemiologia, Hospital Clínic de Barcelona, Barcelona, Spain. [Campins M] Servei de Medicina Preventiva i Epidemiologia, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Fuentes I] Unitat de Suport a la Investigació Clínica, Vall d'Hebron Institut de Recerca (VHIR), Barcelona, Spain. [Agustí A] Servei de Farmacologia Clínica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Departament de Farmacologia, Terapèutica i Toxicologia, Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid35795713
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record